November 26, 2018Diabetes
According to an article published in Diabetes Care (3 October 2018), people with prediabetes or new-onset type 2 diabetes had gastric banding, a type of bariatric surgery for weight loss, had similar stabilization of their disease to those who took metformin alone. The Beta Cell Restoration through Fat Mitigation study, or BetaFat, enrolled 88 participants with mild to moderate obesity and either prediabetes or new-onset type 2 diabetes. Half of the participants were randomly assigned to receive a gastric banding procedure involving placement of a band around the upper part of the stomach to slow digestion, and the other participants received the drug metformin, the most common first-line medication for people with prediabetes and early type 2 diabetes. The BetaFat studywas conducted at the University of Southern California, Los Angeles, in collaboration with Kaiser Permanente Southern California.
After two years, study results showed people in the gastric banding group lost significantly more weight, an average of 23 pounds, compared to four pounds in the metformin group. The two treatment groups also ended up with similar improvements in insulin sensitivity and relatively stable function of insulin-producing cells, with small improvements in blood glucose levels.
These results are part of the Restoring Insulin Secretion (RISE) study, a set of three clinical trials designed to find ways to reverse or slow the loss of insulin production and release in people at risk for type 2 diabetes or recently diagnosed with the disease so that they can stay healthier longer. While BetaFat compared results from surgical weight loss to medication, the two other RISE trials are examining the effects of a variety of medications in youth and adults.